27 January 2013 | 11:07

Leprosy: an ancient disease thrives in 21st century

viewings icon comments icon

ПОДЕЛИТЬСЯ

whatsapp button telegram button facebook button
Photo courtesy of guerrillaexplorer.com Photo courtesy of guerrillaexplorer.com

It has been called the world's oldest recorded disease, an evil that humans have known for more than 3,500 years, as papyri from ancient Egypt testify, AFP reports. Yet drugs to cure leprosy are cheap, plentiful and effective. So why is this biblical curse still around? Doctors speaking ahead of World Leprosy Day on Sunday point to wonderful news about the bid to stamp out this nightmare -- but they also acknowledge sizeable hurdles. "There has been enormous progress in treating and controlling the leprosy epidemic," says British microbiologist Stewart Cole. "Six million people have been cured by multi-drug therapy." Multi-drug therapy, or MDT, is a cocktail of three antibiotics designed to kill the parasitic rod-shaped germ, Mycobacterium leprosae, that after a long incubation spreads from nerve cells to muscles and other tissues. Several drugs are always used, as only one drug enables the germ to develop resistance to it. Without treatment, the microbe causes crippling damage to the hands, skin, the nose and eyes. The condition goes hand-in-hand with ostracism, even though scientists say M. leprosae, transmitted by droplets from the nose and mouth, is generally not very infectious. According to World Health Organisation (WHO) figures, there were roughly 5.2 million people with leprosy in 1985. The burden has fallen sharply, driven especially by free MDT treatment made available by the WHO to poor countries. With it, a leper can be cured in six to 12 months. But even as the WHO is demanding a "final push" against leprosy, the decline in new infections seems to have plateaued. In 2004, there were around 400,000 new cases, which fell to 228,000 new cases in 2010, then to 219,000 in 2011. "The WHO is starting to wonder why this is the case," says Cole, who chairs the scientific and medical commission of the Raoul Follereau Foundation, a French NGO inspired by a 20th-century campaigner. "For years, they told us that if we carried on using MDT, prevalence would gradually hit zero, but this hasn't happened, and we are concerned." Leprosy has been eliminated from 119 countries out of 122 countries where the disease was considered a public health problem in 1985. But tenacious pockets remain in parts of Brazil, Indonesia, Philippines, Democratic Republic of Congo, India, Madagascar, Mozambique, Nepal and Tanzania, according to the UN's health body. -- Medical infrastructure to blame -- Roch Christian Johnson, a leprosy specialist from the West African state of Benin, said one reason is poor medical facilities. Many lepers are already excluded from their communities and clinics are often located far from people in need. As a result, many people fail to get diagnosed swiftly, and the germ incubates unseen for years. Each year, around 12,000 people are diagnosed only after they have reached advanced stages of leprosy, when damage is irreversible, he said. Another problem is multibacillary leprosy, a more contagious form that requires a tougher drug regimen. If undetected and untreated, it leads to more infections, which in turn may only be spotted a decade or two later. Even though funding for research is a long-running concern, scientists say they are gaining useful insights into leprosy. Recent evidence suggests that M. leprosae has a natural reservoir in armadillos. In humans, according to a study published last week, the germ hijacks key cells in the nervous system called Schwann cells and then reprogrammes them into muscle cells, thus helping them to spread into muscle tissue. And a team in Seattle, Washington, is seeking authorisation to carry out a leprosy vaccine on a small group of volunteers, the first in a three-phase trial process. Ultimately, though, wiping out leprosy will come down to commitment and resources, say many. "When I started this work 40 years ago, leprosy was so prevalent that people used to call it 'The Disease'," said Father Christian Steunou, who works at a leprosy treatment centre at Davougon in Benin. "They never called it leprosy, they simply said, 'The Disease'." "Nowadays, though, it's just another illness. The pity is that it's no longer a serious disease but an unrecognised one. "Few caregivers show much interest in it, which means that it can bounce back if we don't take care."

whatsapp button telegram button facebook button copyLink button
Иконка комментария блок соц сети
It has been called the world's oldest recorded disease, an evil that humans have known for more than 3,500 years, as papyri from ancient Egypt testify, AFP reports. Yet drugs to cure leprosy are cheap, plentiful and effective. So why is this biblical curse still around? Doctors speaking ahead of World Leprosy Day on Sunday point to wonderful news about the bid to stamp out this nightmare -- but they also acknowledge sizeable hurdles. "There has been enormous progress in treating and controlling the leprosy epidemic," says British microbiologist Stewart Cole. "Six million people have been cured by multi-drug therapy." Multi-drug therapy, or MDT, is a cocktail of three antibiotics designed to kill the parasitic rod-shaped germ, Mycobacterium leprosae, that after a long incubation spreads from nerve cells to muscles and other tissues. Several drugs are always used, as only one drug enables the germ to develop resistance to it. Without treatment, the microbe causes crippling damage to the hands, skin, the nose and eyes. The condition goes hand-in-hand with ostracism, even though scientists say M. leprosae, transmitted by droplets from the nose and mouth, is generally not very infectious. According to World Health Organisation (WHO) figures, there were roughly 5.2 million people with leprosy in 1985. The burden has fallen sharply, driven especially by free MDT treatment made available by the WHO to poor countries. With it, a leper can be cured in six to 12 months. But even as the WHO is demanding a "final push" against leprosy, the decline in new infections seems to have plateaued. In 2004, there were around 400,000 new cases, which fell to 228,000 new cases in 2010, then to 219,000 in 2011. "The WHO is starting to wonder why this is the case," says Cole, who chairs the scientific and medical commission of the Raoul Follereau Foundation, a French NGO inspired by a 20th-century campaigner. "For years, they told us that if we carried on using MDT, prevalence would gradually hit zero, but this hasn't happened, and we are concerned." Leprosy has been eliminated from 119 countries out of 122 countries where the disease was considered a public health problem in 1985. But tenacious pockets remain in parts of Brazil, Indonesia, Philippines, Democratic Republic of Congo, India, Madagascar, Mozambique, Nepal and Tanzania, according to the UN's health body. -- Medical infrastructure to blame -- Roch Christian Johnson, a leprosy specialist from the West African state of Benin, said one reason is poor medical facilities. Many lepers are already excluded from their communities and clinics are often located far from people in need. As a result, many people fail to get diagnosed swiftly, and the germ incubates unseen for years. Each year, around 12,000 people are diagnosed only after they have reached advanced stages of leprosy, when damage is irreversible, he said. Another problem is multibacillary leprosy, a more contagious form that requires a tougher drug regimen. If undetected and untreated, it leads to more infections, which in turn may only be spotted a decade or two later. Even though funding for research is a long-running concern, scientists say they are gaining useful insights into leprosy. Recent evidence suggests that M. leprosae has a natural reservoir in armadillos. In humans, according to a study published last week, the germ hijacks key cells in the nervous system called Schwann cells and then reprogrammes them into muscle cells, thus helping them to spread into muscle tissue. And a team in Seattle, Washington, is seeking authorisation to carry out a leprosy vaccine on a small group of volunteers, the first in a three-phase trial process. Ultimately, though, wiping out leprosy will come down to commitment and resources, say many. "When I started this work 40 years ago, leprosy was so prevalent that people used to call it 'The Disease'," said Father Christian Steunou, who works at a leprosy treatment centre at Davougon in Benin. "They never called it leprosy, they simply said, 'The Disease'." "Nowadays, though, it's just another illness. The pity is that it's no longer a serious disease but an unrecognised one. "Few caregivers show much interest in it, which means that it can bounce back if we don't take care."
Читайте также
Join Telegram Последние новости
The Moon is calling: New lunar mission
Wolf attacked man in Atyrau region
Euronews office opened in Astana
Earthquake recorded in Zhambyl region
Tokayev sent telegram to Qatar’s Emir
A New Year gift guide for her
Tokayev expressed condolences to Macron
Bitcoin exchange rate hit a new record
EU expanded sanctions against Belarus
Kazhydromet warned residents of Almaty
Лого TengriNews мобильная Лого TengriSport мобильная Лого TengriLife мобильная Лого TengriAuto мобильная Иконка меню мобильная
Иконка закрытия мобильного меню
Открыть TengriNews Открыть TengriLife Открыть TengriSport Открыть TengriTravel Открыть TengriGuide Открыть TengriEdu Открыть TengriAuto

Exchange Rates

 523.95  course up  543.16  course up  5.1  course up

 

Weather

 

Редакция Advertising
Социальные сети
Иконка Instagram footer Иконка Telegram footer Иконка Vkontakte footer Иконка Facebook footer Иконка Twitter footer Иконка Youtube footer Иконка TikTok footer Иконка WhatsApp footer